Calling this number connects you with a Patient Advocate at The Mesothelioma Center, the nation's most trusted mesothelioma resource.
Our Patient Advocates can help guide you or your loved one through the steps to take after a mesothelioma diagnosis. Our team has a combined experience of more than 30 years in assisting cancer patients, and includes a medical doctor, an oncology registered nurse and a U.S. Navy veteran.
Cediranib is an experimental anti-angiogenesis drug that helps control tumor growth and metastasis. Researchers are testing it in combination with chemotherapy drugs. It has produced mixed results in clinical trials for pleural mesothelioma patients.
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
Assisting mesothelioma patients and their loved ones since 2006.
Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
A+ rating from the Better Business Bureau.
5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Cediranib is an anti-angiogenesis drug, similar to bevacizumab (Avastin). It works by blocking a type of protein called vascular endothelial growth factors (VEGF).
The body uses VEGF to grow new blood vessels and heal itself. This process is called angiogenesis. However, tumors also rely on angiogenesis to grow and spread cancer cells throughout the body.
Cediranib Fast Facts
Blocks formation of new blood vessels and tissue healing
Prevents tumor growth and cancer metastasis
Tested in clinical trials with standard chemotherapy
Side effects include diarrhea and high blood pressure
Halting angiogenesis can starve tumors and prevent metastasis, but it can also cause severe side effects for patients. The main challenge for researchers is safely adding anti-angiogenesis drugs into chemotherapy regimens.
Cediranib has not been approved by the U.S. Food and Drug Administration. Various clinical trials are testing cediranib for solid tumors, including pleural mesothelioma.
Find a Mesothelioma Cancer Center
Access top mesothelioma cancer centers that have experience treating this rare disease.
Early clinical trials tested high-dose cediranib after chemotherapy. These high doses resulted in many complications and little benefit.
More recent trials have tried lower-dose cediranib in combination with standard chemotherapy, however, they have also produced weak results. A 2021 clinical research study ended with similar results, concluding that single-agent approaches are futile and should be tested in combination with chemotherapy or in a multimodality setting.
In 2011, the Journal of Thoracic Oncology published the results of a phase II study. Researchers evaluated 47 pleural mesothelioma patients. The patients received a daily 45 mg dose of cediranib after finishing chemotherapy.
Tumors shrank in four of the patients, but more than half the study group experienced fatigue, diarrhea and high blood pressure. Almost all the patients required a dose reduction.
A 2012 article in Lung Cancer reported the results of a similar phase II trial which evaluated 50 patients. Patients were initially given 45 mg of cediranib each day. The researchers later lowered the dose to 30 mg.
The researchers observed that disease control was better at the higher dose, but it resulted in many severe side effects.
Research for a new type of mesothelioma treatment is underway at the Netherlands Cancer Institute. Scientists are exploring a novel combination of existing…
In 2017, the Journal of Thoracic Oncology reported on a phase I trial combining cediranib with standard chemotherapy for pleural mesothelioma. The researchers determined that a 20 mg daily dose of cediranib was reasonably safe to take in between cycles of Alimta (pemetrexed) and cisplatin.
The following year, researchers conducted a phase II trial with 92 pleural mesothelioma patients. Some of the patients received standard chemotherapy and cediranib, while the others received chemotherapy plus a placebo.
Median survival was 10 months for the cediranib group and 8.5 months for the placebo group. The cediranib group was about three times more likely to experience diarrhea and high blood pressure.
Patients interested in experimental treatments should talk to an experienced mesothelioma specialist about which clinical trials may be right for them.
Our free mesothelioma guide contains information on symptoms, top doctors, support resources and more. Get information tailored to your unique diagnosis, and learn about our free services.
Request Your Free Guide Today
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
